Precision Biosciences (DTIL) closed at $7.47 on October 28, 2026, up 10.0% from the previous close, on volume of 182,883 shares (30-day average 251,353).
Data as of October 28, 2026.
Precision BioSciences to Report Third Quarter 2026 Financial Results on November 3, 2026
Business Wire (Thu, 29-Oct 7:01 AM ET)
Analysts Are Bullish on Top Healthcare Stocks: Precision BioSciences (DTIL), ProKidney (PROK)
TipRanks (Thu, 29-Oct 4:40 AM ET)
Business Wire (Thu, 8-Oct 7:01 AM ET)
Business Wire (Thu, 27-Aug 8:00 AM ET)
Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study
Business Wire (Mon, 24-Aug 6:01 AM ET)
Business Wire (Thu, 20-Aug 8:00 AM ET)
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Business Wire (Thu, 6-Aug 7:01 AM ET)
Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026
Business Wire (Fri, 31-Jul 7:01 AM ET)
Market Chameleon (Thu, 12-Mar 3:50 AM ET)
Market Chameleon (Mon, 9-Mar 3:59 AM ET)
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
Precision Biosciences trades on the NASDAQ stock market under the symbol DTIL.
As of October 29, 2026, DTIL stock price climbed to $7.51 with 81,364 million shares trading.
DTIL has a beta of 1.54, meaning it tends to be more sensitive to market movements. DTIL has a correlation of 0.07 to the broad based SPY ETF.
DTIL has a market cap of $207.29 million. This is considered a Small Cap stock.
Last quarter Precision Biosciences reported $0 in Revenue and -$1.26 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.58.
In the last 3 years, DTIL traded as high as $19.43 and as low as $3.53.
The top ETF exchange traded funds that DTIL belongs to (by Net Assets): VTI, IWM, VXF, IWN, FESM.
DTIL has underperformed the market in the last year with a return of -9.4%, while SPY returned +12.9%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in DTIL shares. However, DTIL has outperformed the market in the last 3 month and 2 week periods, returning +4.7% and +24.5%, while SPY returned +4.0% and -0.2%, respectively. This indicates DTIL has been having a stronger performance recently.
DTIL support price is $7.12 and resistance is $7.82 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DTIL shares will trade within this expected range on the day.
